DOCSLIB.ORG

Genetic Testing in a Cohort of Patients with Potential Epilepsy With

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetic Testing in a Cohort of Patients with Potential Epilepsy With Epilepsy Research 150 (2019) 70–77 Contents lists available at ScienceDirect Epilepsy Research journal homepage: www.elsevier.com/locate/epilepsyres Genetic testing in a cohort of patients with potential epilepsy with myoclonic-atonic seizures T ⁎ Katie Angione , Krista Eschbach, Garnett Smith, Charuta Joshi, Scott Demarest University of Colorado Denver, Department of Pediatrics, Section of Neurology, United States ARTICLE INFO ABSTRACT Keywords: Epilepsy with myoclonic-atonic seizures (EMAS) accounts for 1–2% of all childhood-onset epilepsies. EMAS has Epilepsy been shown to have an underlying genetic component, however the genetics of this disorder is not yet well Myoclonic atonic understood. The purpose of this study was to review genetic testing results for a cohort of EMAS patients. A Doose retrospective chart review was conducted for 77 patients evaluated at Children’s Hospital Colorado with a po- Genetics tential diagnosis of EMAS. Genetic testing and biochemical testing was reviewed. Family history data was also collected. Seventy-seven percent of the cohort had at least one genetic test performed, and a molecular diagnosis was reached for six patients. Thirty-seven patients had a microarray, six of which identified a copy number variant. Only one was felt to contribute to the phenotype (2p16.3 deletion including NRXN1). Fifty-one patients had an epilepsy panel, two of which were positive (likely pathogenic variant in SCN1A, pathogenic variant in GABRG2). Of the six patients who had whole exome sequencing, two were negative, three were positive or likely positive, and one had multiple variants not felt to explain the phenotype. While EMAS is widely accepted to have a strong genetic component, the diagnostic yield of genetic testing remains low. This may be because several genes now thought to be associated with EMAS are not included on the more commonly ordered epilepsy panels, or have only recently been added to them. 1. Introduction polygenic in some cases Kelley and Kossoff, 2010; Doose et al., 1970; Tang and Pal, 2012. This has complicated the identification of clear Epilepsy with myoclonic-atonic seizures (EMAS), also known as genetic etiologies. While several genes have been associated with Doose syndrome, is an epilepsy syndrome accounting for one to two EMAS, (including SCN1A (Ebach et al., 2005; Escayg et al., 2001), percent of all childhood-onset epilepsies (Kelley and Kossoff, 2010). SCN1B (Kelley and Kossoff, 2010; Scheffer et al., 2001; Wallace et al., EMAS is characterized by multiple seizure types with onset typically 1998), SCN2A Scheffer et al., 2001; Sugawara et al., 2001; Wolff et al., between one and five years of life (Kelley and Kossoff, 2010). Devel- 2017), GABRG2 ( Kelley and Kossoff, 2010; Scheffer et al., 2001; Kang opment is usually normal prior to seizure onset, with a subsequent and Macdonald, 2016), CHD2 (Meller et al., 2017), STX1B (Vlaskamp plateau or regression in most patients. et al., 2016), SLC2A1 (Larsen et al., 2015; Mullen et al., 2011), SLC6A1 Since first described by Dr. Hermann Doose in 1970, the disorder (Carvill et al., 2015; Johnannesen et al., 2018), and GABRB3 (Meller has been felt to have an underlying genetic component given the high et al., 2017)), analysis of these genes in previously reported EMAS prevalence of epilepsy and EEG abnormalities among family members cohorts has yielded positive results in a minority of patients, suggesting of affected individuals. In Doose’s original cohort of 117 patients with that the genetics of EMAS remains poorly understood. The purpose of EMAS, 32% had a positive family history of seizures, while 68–80% had this study is to assess the testing practices and diagnostic yield of a family history of abnormal EEG findings (Kelley and Kossoff, 2010; clinical genetic evaluations in patients with a potential diagnosis of Doose et al., 1970). However, the prevalence of myoclonic or atonic EMAS at a tertiary epilepsy center, as well as to review the existing seizures among family members was much lower (about two percent), literature regarding genetic associations with EMAS. suggesting significant phenotypic variability within affected families (Kelley and Kossoff, 2010; Doose et al., 1970). 2. Material and methods The variability of presentation among individuals with EMAS and their family members suggests that inheritance may be multifactorial or A retrospective chart review was conducted at Children’s Hospital ⁎ Corresponding author at: 13123 E 16th Avenue, B155, Aurora, CO, 80045, United States. E-mail address: [email protected] (K. Angione). https://doi.org/10.1016/j.eplepsyres.2019.01.008 Received 4 September 2018; Received in revised form 10 January 2019; Accepted 13 January 2019 Available online 14 January 2019 0920-1211/ © 2019 Elsevier B.V. All rights reserved. K. Angione et al. Epilepsy Research 150 (2019) 70–77 Colorado. Patients were identified from a clinical database of patients with a potential diagnosis of EMAS. The database included children with epilepsy onset between May 2004 and April 2017. Eligibility cri- teria included consideration of a diagnosis of EMAS by a child neu- rology faculty member at any point in the patient’s course. A definitive diagnosis of EMAS was not required. Patients were excluded if on de- tailed review they never had any clinical or electrographic evidence of drop seizures. Drop seizures were defined as a brief, sudden event that could cause the patient to fall. Additionally, patients were excluded if they had a clear structural etiology on imaging. The cohort was defined by these clinically relevant parameters as evolution of individual pa- tient phenotype over time can result in diagnosis switching and delay in final diagnosis (Eschbach et al., 2018), yet genetic testing may already be completed prior to this time. The full electroclinical spectrum of this cohort and diagnosis switching is described in detail in the initial Fig. 1. Results of biochemical and genetic testing for patients with suspected publication on this cohort (Eschbach et al., 2018). Genetic testing was EMAS. Black represents the percentage of patients with positive (abnormal) test results, dark gray represents patients with variants of uncertain significance, reviewed, including chromosomal microarray, mitochondrial DNA and light gray represents patients with normal testing. analysis, single gene testing, epilepsy panels, and whole exome se- quencing (WES). Overall percentage of the cohort tested for key genes previously associated with EMAS (SCN1A, SCN1B, SCN2A, GABRG2, analyzed ranging from 38 – 89. This variability depended on the type of CHD2, STX1B, SLC2A1, SLC6A1, and GABRB3) through any form of epilepsy panel ordered and date of testing. Some of these panels have testing was noted. For variants of uncertain significance (VUS), results been updated over time as new genes have been discovered (including of parental testing were also noted. Results of panel testing were con- several genes with a proposed association with EMAS), so the presence sidered “normal” if completely negative, or if all variants were identi- or absence of these genes was noted for each patient’s panel. Overall, 51 fied in a heterozygous state in an autosomal recessive gene, in which patients (66%) had an epilepsy panel. Thirty-nine of these (76.5%) case they would not be expected to be clinically relevant. were normal, including 24 negative panels and 15 with one or more Pertinent biochemical testing was also reviewed to identify any heterozygous variants in autosomal recessive genes. Ten patients metabolic abnormalities and to assess the utility of this testing in an (19.6%) had variants of uncertain significance in autosomal dominant EMAS cohort. This included 3-methylglutaconic acid, acylcarnitine, genes, including three in the GABRG2 gene, which has previously been serum amino acids, ammonia, glucose, lactate, pyruvic acid, very long associated with EMAS. Of the GABRG2 variants identified, two were chain fatty acids, urine organic acids, and cerebrospinal fluid studies inherited from asymptomatic fathers and the inheritance is unknown (amino acids, glucose, BH4/neopterin, folate/5MTHF, neuro- for the other. Specifics of these patients’ clinical presentations are transmitters, protein, and pyridoxal-5-phosphate). shown in Table 1B. The remaining seven patients had variants which Family history data was collected to determine the prevalence of were inherited from an asymptomatic parent and /or were inconsistent epilepsy family history in the cohort and to assess whether familial with the patient’s clinical presentation (Supplemental Table 1). Two variants had been inherited from symptomatic or asymptomatic in- patients (4%) were found to have pathogenic variants, one in the dividuals. Family history was specifically reviewed for childhood onset SCN1A gene and one in the GABRG2 gene, both of which have pre- epilepsy, febrile seizures, intellectual disability, and autism, and any viously been associated with EMAS. The overall yield of genetic testing other relevant neurodevelopmental history was also noted. All data in this cohort for the genes most commonly associated with EMAS is analyses were descriptive in nature using frequencies and percentages. shown in Fig. 2. This study was reviewed and approved by the University of Colorado Of the six patients who had whole exome sequencing, two were Multiple Institutional Review Board (COMIRB) with waiver of consent. negative and one had variants of uncertain significance in NIPA1, SZT2, and FAH. Three patients had abnormal findings which were felt to at 3. Results least partially explain their symptoms, including a de novo pathogenic variant in CHD2,ade novo likely pathogenic variant in CSNK2A1, and The cohort consisted of 77 patients with a suspected diagnosis of compound heterozygous variants in PIGN. EMAS, including 19 females (25%) and 58 males (75%). As described in Of the 72 patients (93.5%) who had biochemical testing, only one the earlier publication regarding this cohort, 50 patients (65%) had a (1.4%) had abnormal results significant enough to prompt additional change in epilepsy diagnosis over time and 57 patients (74%) had a studies, which was an elevation of 3-methylglutaconic acid.
Load more

Recommended publications
  • Status Epilepticus Clinical Pathway
    JOHNS HOPKINS ALL CHILDREN’S HOSPITAL Status Epilepticus Clinical Pathway 1 Johns Hopkins All Children's Hospital Status Epilepticus Clinical Pathway Table of Contents 1. Rationale 2. Background 3. Diagnosis 4. Labs 5. Radiologic Studies 6. General Management 7. Status Epilepticus Pathway 8. Pharmacologic Management 9. Therapeutic Drug Monitoring 10. Inpatient Status Admission Criteria a. Admission Pathway 11. Outcome Measures 12. References Last updated: July 7, 2019 Owners: Danielle Hirsch, MD, Emergency Medicine; Jennifer Avallone, DO, Neurology This pathway is intended as a guide for physicians, physician assistants, nurse practitioners and other healthcare providers. It should be adapted to the care of specific patient based on the patient’s individualized circumstances and the practitioner’s professional judgment. 2 Johns Hopkins All Children's Hospital Status Epilepticus Clinical Pathway Rationale This clinical pathway was developed by a consensus group of JHACH neurologists/epileptologists, emergency physicians, advanced practice providers, hospitalists, intensivists, nurses, and pharmacists to standardize the management of children treated for status epilepticus. The following clinical issues are addressed: ● When to evaluate for status epilepticus ● When to consider admission for further evaluation and treatment of status epilepticus ● When to consult Neurology, Hospitalists, or Critical Care Team for further management of status epilepticus ● When to obtain further neuroimaging for status epilepticus ● What ongoing therapy patients should receive for status epilepticus Background: Status epilepticus (SE) is the most common neurological emergency in children1 and has the potential to cause substantial morbidity and mortality. Incidence among children ranges from 17 to 23 per 100,000 annually.2 Prevalence is highest in pediatric patients from zero to four years of age.3 Ng3 acknowledges the most current definition of SE as a continuous seizure lasting more than five minutes or two or more distinct seizures without regaining awareness in between.
    [Show full text]
  • Clinicians Using the Classification Will Identify a Seizure As Focal Or Generalized Onset If There Is About an 80% Confidence Level About the Type of Onset
    GENERALIZED ONSET SEIZURES Generalized onset seizures are not characterized by level of awareness, because awareness is almost always impaired. Generalized tonic-clonic: Immediate loss of Generalized epileptic spasms: Brief seizures with awareness, with stiffening of all limbs (tonic phase), flexion at the trunk and flexion or extension of the followed by sustained rhythmic jerking of limbs and limbs. Video-EEG recording may be required to face (clonic phase). Duration is typically 1 to 3 minutes. determine focal versus generalized onset. The seizure may produce a cry at the start, falling, tongue biting, and incontinence. Generalized typical absence: Sudden onset when activity stops with a brief pause and staring, Generalized clonic: Rhythmical sustained jerking of sometimes with eye fluttering and head nodding or limbs and/or head with no tonic stiffening phase. other automatic behaviors. If it lasts for more than These seizures most often occur in young children. several seconds, awareness and memory are impaired. Recovery is immediate. The EEG during these seizures Generalized tonic: Stiffening of all limbs, without always shows generalized spike-waves. clonic jerking. Generalized atypical absence: Like typical absence Generalized myoclonic: Irregular, unsustained jerking seizures, but may have slower onset and recovery and of limbs, face, eyes, or eyelids. The jerking of more pronounced changes in tone. Atypical absence generalized myoclonus may not always be left-right seizures can be difficult to distinguish from focal synchronous, but it occurs on both sides. impaired awareness seizures, but absence seizures usually recover more quickly and the EEG patterns are Generalized myoclonic-tonic-clonic: This seizure is like different.
    [Show full text]
  • Neuropathology Category Code List
    Neuropathology Page 1 of 27 Neuropathology Major Category Code Headings Revised 10/2018 1 General neuroanatomy, pathology, and staining 65000 2 Developmental neuropathology, NOS 65400 3 Epilepsy 66230 4 Vascular disorders 66300 5 Trauma 66600 6 Infectious/inflammatory disease 66750 7 Demyelinating diseases 67200 8 Complications of systemic disorders 67300 9 Aging and neurodegenerative diseases 68000 10 Prion diseases 68400 11 Neoplasms 68500 12 Skeletal Muscle 69500 13 Peripheral Nerve 69800 14 Ophthalmic pathology 69910 Neuropathology Page 2 of 27 Neuropathology 1 General neuroanatomy, pathology, and staining 65000 A Neuroanatomy, NOS 65010 1 Neocortex 65011 2 White matter 65012 3 Entorhinal cortex/hippocampus 65013 4 Deep (basal) nuclei 65014 5 Brain stem 65015 6 Cerebellum 65016 7 Spinal cord 65017 8 Pituitary 65018 9 Pineal 65019 10 Tracts 65020 11 Vascular supply 65021 12 Notochord 65022 B Cell types 65030 1 Neurons 65031 2 Astrocytes 65032 3 Oligodendroglia 65033 4 Ependyma 65034 5 Microglia and mononuclear cells 65035 6 Choroid plexus 65036 7 Meninges 65037 8 Blood vessels 65038 C Cerebrospinal fluid 65045 D Pathologic responses in neurons and axons 65050 1 Axonal degeneration/spheroid/reaction 65051 2 Central chromatolysis 65052 3 Tract degeneration 65053 4 Swollen/ballooned neurons 65054 5 Trans-synaptic neuronal degeneration 65055 6 Olivary hypertrophy 65056 7 Acute ischemic (hypoxic) cell change 65057 8 Apoptosis 65058 9 Protein aggregation 65059 10 Protein degradation/ubiquitin pathway 65060 E Neuronal nuclear inclusions 65100
    [Show full text]
  • Myoclonic Status Epilepticus in Juvenile Myoclonic Epilepsy
    Original article Epileptic Disord 2009; 11 (4): 309-14 Myoclonic status epilepticus in juvenile myoclonic epilepsy Julia Larch, Iris Unterberger, Gerhard Bauer, Johannes Reichsoellner, Giorgi Kuchukhidze, Eugen Trinka Department of Neurology, Medical University of Innsbruck, Austria Received April 9, 2009; Accepted November 18, 2009 ABSTRACT – Background. Myoclonic status epilepticus (MSE) is rarely found in juvenile myoclonic epilepsy (JME) and its clinical features are not well described. We aimed to analyze MSE incidence, precipitating factors and clini- cal course by studying patients with JME from a large outpatient epilepsy clinic. Methods. We retrospectively screened all patients with JME treated at the Department of Neurology, Medical University of Innsbruck, Austria between 1970 and 2007 for a history of MSE. We analyzed age, sex, age at seizure onset, seizure types, EEG, MRI/CT findings and response to antiepileptic drugs. Results. Seven patients (five women, two men; median age at time of MSE 31 years; range 17-73) with MSE out of a total of 247 patients with JME were identi- fied. The median follow-up time was seven years (range 0-35), the incidence was 3.2/1,000 patient years. Median duration of epilepsy before MSE was 26 years (range 10-58). We identified three subtypes: 1) MSE with myoclonic seizures only in two patients, 2) MSE with generalized tonic clonic seizures in three, and 3) generalized tonic clonic seizures with myoclonic absence status in two patients. All patients responded promptly to benzodiazepines. One patient had repeated episodes of MSE. Precipitating events were identified in all but one patient. Drug withdrawal was identified in four patients, one of whom had additional sleep deprivation and alcohol intake.
    [Show full text]
  • Neuronal Hyperexcitability in a Mouse Model of SCN8A Epileptic Encephalopathy
    Neuronal hyperexcitability in a mouse model of SCN8A epileptic encephalopathy Luis F. Lopez-Santiagoa,1, Yukun Yuana,1, Jacy L. Wagnonb, Jacob M. Hulla, Chad R. Frasiera, Heather A. O’Malleya, Miriam H. Meislerb,c, and Lori L. Isoma,c,d,2 aDepartment of Pharmacology, University of Michigan, Ann Arbor, MI 48109; bDepartment of Human Genetics, University of Michigan, Ann Arbor, MI 48109; cDepartment of Neurology, University of Michigan, Ann Arbor, MI 48109; and dDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109 Edited by William A. Catterall, University of Washington School of Medicine, Seattle, WA, and approved January 17, 2017 (received for review October 12, 2016) Patients with early infantile epileptic encephalopathy (EIEE) experi- include seizure onset between birth and 18 mo of age, mild to se- ence severe seizures and cognitive impairment and are at increased vere cognitive and developmental delay, and mild to severe risk for sudden unexpected death in epilepsy (SUDEP). EIEE13 [Online movement disorders (11, 13). Approximately 50% of patients are Mendelian Inheritance in Man (OMIM) # 614558] is caused by de nonambulatory and 12% of published cases (5/43) experienced novo missense mutations in the voltage-gated sodium channel gene SUDEP during childhood or adolescence (10, 13, 16, 17). SCN8A. Here, we investigated the neuronal phenotype of a mouse Almost all of the identified mutations in SCN8A are missense model expressing the gain-of-function SCN8A patient mutation, mutations. Ten of these mutations have been tested functionally in p.Asn1768Asp (Nav1.6-N1768D). Our results revealed regional transfected cells, and eight were found to introduce changes in the and neuronal subtype specificity in the effects of the N1768D muta- biophysical properties of Na 1.6 that are predicted to result in Scn8aN1768D/+ v tion.
    [Show full text]
  • Myoclonic Atonic Epilepsy Another Generalized Epilepsy Syndrome That Is “Not So” Generalized
    EDITORIAL Myoclonic atonic epilepsy Another generalized epilepsy syndrome that is “not so” generalized John M. Zempel, MD, Myoclonic atonic/astatic epilepsy (MAE), first described have shown predominant thalamic activation PhD well by Doose1 (pronounced dough sah: http://www. and default mode network deactivation.6–8 Even Tadaaki Mano, MD, PhD youtube.com/watch?v5hNNiWXV2wF0), is a general- Lennox-Gastaut syndrome, a devastating epileptic ized electroclinical syndrome with early onset charac- encephalopathy with EEG findings of runs of slow terized by myoclonic, atonic/astatic, generalized spike and wave and paroxysmal higher frequency Correspondence to tonic-clonic, and absence seizures (but not tonic activity, has fMRI correlates that are more focal than Dr. Zempel: [email protected] seizures) in association with generalized spike-wave expected in a syndrome with widespread EEG (GSW) discharges. Thought to have a genetic com- abnormalities.9,10 Neurology® 2014;82:1486–1487 ponent that has proven to be complicated,2 MAE EEG-fMRI is maturing as a research and clinical sometimes occurs in children who have otherwise technique. Recording scalp EEG in an electrically been developing normally and has variable outcome. hostile environment is not an easy task. Substantial MAE is typically treated with antiseizure medications technical artifacts, such as changing imaging gradients that are used for generalized epilepsy syndromes, with and ballistocardiogram (ECG-linked artifact observed perhaps a best response to valproate, felbamate, or the in the scalp electrodes), contaminate the EEG signal. ketogenic diet.3,4 However, the relatively distinctive EEG discharges in In this issue of Neurology®, Moeller et al.5 report patients with epilepsy have partially circumvented on the fMRI correlates of GSW discharges as mea- this problem.
    [Show full text]
  • “Seizures (Epilepsy)” a Seizure: Partial – Start in a Specific Part of the Brain, Not in the Whole Is a Symptom of an Electrical Disturbance in the Brain Brain
    “Seizures (Epilepsy)” A seizure: Partial – start in a specific part of the brain, not in the whole Is a symptom of an electrical disturbance in the brain brain. Unlike generalized seizures, partial seizures can have a Is a rare event warning before they occur (aura). Auras are actually a kind of Has a typical beginning (best clue for accurate diagnosis) seizure. There are several different kinds of partial seizures: Is involuntary simple (motor, sensory or psychological), complex, partial Lasts only a short time (90% complete in 90 seconds) seizure with secondary generalization. May cause post seizure impairments. Most seizures do not involve convulsions. Accurate seizure diagnosis by the health care provider is very The most common type of seizure is one mostly involving important because the medications used to treat seizures often vary loss of awareness. depending on the type. There are 20 types of seizures in the Seizures can be very subtle and hard to notice. International Classification of Seizures (over 2,000 types reported in the literature). Examples of post-seizure impairments: A detailed description of the seizure by the person observing the Post ictal confusion (length is individual) seizure is necessary for accurate diagnosing. Having a seizure while in Initial difficulty speaking the doctor’s office is very rare. Confusion about when, where, or what was just happening Memory disturbance which can last a while (behaving Seizure observation: - 3 important ones to make (in order of usual normally but can’t retain/absorb information) importance): Headache with some kinds of seizures What happened right as the seizure was beginning? What is epilepsy? What happened after the seizure was over? What happened during the seizure? Epilepsy is a condition where a person has “recurrent, unprovoked” seizures.
    [Show full text]
  • Reviews Familial Cortical Myoclonic Tremor and Epilepsy, an Enigmatic Disorder: from Phenotypes to Pathophysiology and Genetics
    Freely available online Reviews Familial Cortical Myoclonic Tremor and Epilepsy, an Enigmatic Disorder: From Phenotypes to Pathophysiology and Genetics. A Systematic Review 1 1 2,3 1* Tom van den Ende , Sarvi Sharifi , Sandra M. A. van der Salm & Anne-Fleur van Rootselaar 1 Department of Neurology and Clinical Neurophysiology, Amsterdam Neuroscience, Academic Medical Center, Amsterdam, The Netherlands, 2 Brain Center Rudolf Magnus, Department of Neurology and Neurosurgery, University Medical Center, Utrecht, The Netherlands, 3 Stichting Epilepsie Instellingen Nederland (SEIN), Zwolle, The Netherlands Abstract Background: Autosomal dominant familial cortical myoclonic tremor and epilepsy (FCMTE) is characterized by distal tremulous myoclonus, generalized seizures, and signs of cortical reflex myoclonus. FCMTE has been described in over 100 pedigrees worldwide, under several different names and acronyms. Pathological changes have been located in the cerebellum. This systematic review discusses the clinical spectrum, treatment, pathophysiology, and genetic findings. Methods: We carried out a PubMed search, using a combination of the following search terms: cortical tremor, myoclonus, epilepsy, benign course, adult onset, familial, and autosomal dominant; this resulted in a total of 77 studies (761 patients; 126 pedigrees) fulfilling the inclusion and exclusion criteria. Results: Phenotypic differences across pedigrees exist, possibly related to underlying genetic differences. A ‘‘benign’’ phenotype has been described in several Japanese families and pedigrees linked to 8q (FCMTE1). French patients (5p linkage; FCMTE3) exhibit more severe progression, and in Japanese/Chinese pedigrees (with unknown linkage) anticipation has been suggested. Preferred treatment is with valproate (mind teratogenicity), levetiracetam, and/or clonazepam. Several genes have been identified, which differ in potential pathogenicity. Discussion: Based on the core features (above), the syndrome can be considered a distinct clinical entity.
    [Show full text]
  • Managing Children with Epilepsy School Nurse Guide
    MANAGING CHILDREN WITH EPILEPSY SCHOOL NURSE GUIDE ACKNOWLEDGEMENTS TO THOSE WHO HAVE CONTRIBUTED TO THE NOTEBOOK Children’s Hospital of Orange County Melodie Balsbaugh, RN Sue Nagel, RN Giana Nguyen, CHOC Institutes Fullerton School District Jane Bockhacker, RN Orange Unified School District Andrea Bautista, RN Martha Boughen, RN Karen Hanson, RN TABLE OF CONTENTS I. EPILEPSY What is epilepsy? Facts about epilepsy Basic neuroanatomy overview Classification of epileptic seizures Diagnostic Tests II. TREATMENT Medications Vagus Nerve Stimulation Ketogenic Diet Surgery III. SAFETY First Aid IV. SPECIAL CONCERNS MedicAlert Helmets Driving Employment and the law V. EPILEPSY AT SCHOOL School epilepsy assessment tool Seizure record Teaching children about epilepsy lesson plan Creating your own individualized health care plan VI. RESOURCES/SUPPORT GROUPS VII. ACCESS TO HEALTHCARE CHOC Epilepsy Center After-Hours Care After Hours Health Care Advice Healthy Families California Kids MediCal CHOC Clinics Healthy Tomorrows VIII. REFERENCES EPILEPSY WHAT IS EPILEPSY? Epilepsy is a neurological disorder. The brain contains millions of nerve cells called neurons that send electrical charges to each other. A seizure occurs when there is a sudden and brief excess surge of electrical activity in the brain between nerve cells. This results in an alteration in sensation, behavior, and consciousness. Seizures may be caused by developmental problems before birth, trauma at birth, head injury, tumor, structural problems, vascular problems (i.e. stroke, abnormal blood vessels), metabolic conditions (i.e. low blood sugar, low calcium), infections (i.e. meningitis, encephalitis) and idiopathic causes. Children who have idiopathic seizures are most likely to respond to medications and outgrow seizures.
    [Show full text]
  • EFNS Guidelines for the Use of Intravenous Immunoglobulin In
    European Journal of Neurology 2008, 15: 893–908 doi:10.1111/j.1468-1331.2008.02246.x EFNS TASK FORCE/CME ARTICLE EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases Members of the Task Force: I. Elovaaraa, S. Apostolskib, P. van Doornc, N. E. Gilhusd, A. Hietaharjue, J. Honkaniemif, I. N. van Schaikg, N. Scoldingh, P. Soelberg Sørenseni and B. Uddj aDepartment of Neurology and Rehabilitation, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland; bInstitute of Neurology, School of Medicine, University of Belgrade, Belgrade, Serbia; cDepartment of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands; dDepartment of Neurology, Haukeland University Hospital, Bergen, Norway; eDepartment of Neurology and Rehabilitation, Tampere University Hospital, Tampere, Finland; fDepartment of Neurology, Vaasa Central Hospital, Vaasa, Finland; gDepartment of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; hUniversity of Bristol Institute Of Clinical Neuroscience, Frenchary Hospital UK Bristol, UK; iDepartment of Neurology, National University Hospital, Rigshospitalet, Copenhagen, Denmark; and jDepartment of Neurology and Rehabilitation, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland Keywords: Despite high-dose intravenous immunoglobulin (IVIG) is widely used in treatment of acute disseminated a
    [Show full text]
  • Evaluation of Behavior and Cognitive Function in Children with Myoclonic
    & The ics ra tr pe ia u Niimi et al., Pediat Therapeut 2013, 3:3 t i d c e s P DOI: 10.4172/2161-0665.1000159 Pediatrics & Therapeutics ISSN: 2161-0665 Case Report Open Access Evaluation of Behavior and Cognitive Function in Children with Myoclonic Astatic Epilepsy Taemi Niimi1, Yuji Inaba1, Mitsuo Motobayashi1, Takafumi Nishimura1, Naoko Shiba1, Tetsuhiro Fukuyama2, Tsukasa Higuchi3, and Kenichi Koike1 1Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan 2Department of Pediatric Neurology, Nagano Children’s Hospital, Azumino, Japan 3Department of General Pediatrics, Nagano Children’s Hospital, Azumino, Japan Abstract Background: Myoclonic astatic epilepsy (MAE) is an idiopathic and generalized childhood epileptic syndrome. Although several studies have reported on cognitive function and intellectual outcome in MAE, little is known about the behavioral problems associated with this disease. The aim of this study was to clarify behavior and cognitive function in children with MAE. Methods: Four children who were diagnosed as having MAE using the proposed criteria of the International Classification of Epilepsies were retrospectively analyzed using patient records with regard to clinical and neuropsychological findings such as age of seizure onset, semiology and severity of seizures, treatment course, behavioral problems, EEG findings, and WISC-III and Pervasive Developmental Disorders Autism Society Japan Rating Scale (PARS) scores that indicate the tendency of autistic behaviors. Results: Disease onset in our cohort ranged from 9 to 35 months of age. Seizures were controlled within 3-8 months over a follow-up period of 4-12 years. All patients had borderline normal intelligence (mean IQ: 75.8 at 5-7 years of age) and exhibited impaired coordination, clumsiness, hyperactivity or impulsivity, and impaired social interaction after improvement of seizures.
    [Show full text]
  • Epileptic Encephalopathy
    Epileptic Encephalopathy ศ. นพ. อนันตน์ ิตย ์ วิสทุ ธิพนั ธ์ Division of Neurology, Department of Pediatrics, Faculty of Medicine-Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Scope of Talk • Overview of Epileptic Encephalopathy • Issues in epileptic encephalopathy • Frequently seen epileptic encephalopathy • Application to daily practice in reality • Q & A What is Epileptic Encephalopathy? Epileptic Encephalopathy • 1840: First described by West WJ from the letter to The Lancet describing “West syndrome” • 1955: Illingworth RS reported 12 cases of “sudden mental deterioration with convulsion in infancy” • 1966: Gastaut H “EE related to the concept that the underlying epileptic activity may contribute to the neurodevelopmental compromise noted in children with early onset, severe epilepsy and abundant spike and wave activities” Epileptic Encephalopathy • 1841 West syndrome • 1957 Landau-Kleffner syndrome • 1960 Lennox-Gastaut syndrome • 1987 Myoclonic-atonic (-astatic) epilepsy • 1971 Electrical Status Epilepticus during sleep (ESES) & Continuous Spikes and Waves during Sleep (CSWS) • 1976 Early Infantile Epileptic Encephalopathy (EIEE) • 1978 Severe Myoclonic Epilepsy in Infancy (SMEI) or Dravet syndrome • ………………………………………….. Epileptic Encephalopathy ILAE 2001: “A condition where the epileptiform abnormalities themselves are believed to contribute to the progressive disturbance of cerebral function” Single Insult Epileptic Encephalopathy or Cause Epilepsy Cognitive dysfunction Delayed Behavioral Development impairment Epileptic
    [Show full text]